Efficacy and safety of dienogest on ovarian endometrioma
10.3760/cma.j.cn112141-20240516-00282
- VernacularTitle:地诺孕素对卵巢子宫内膜异位囊肿的疗效及安全性研究
- Author:
Jiafan SUN
1
;
Xianglian WANG
;
Wennian YU
;
Siyi PAN
;
Yan DING
;
Huihua DAI
;
Xiuli WANG
Author Information
1. 南京医科大学第一临床医学院妇产科学系，南京 210029
- Keywords:
Endometriosis;
Ovarian cysts;
Treatment outcome;
Dienogest
- From:
Chinese Journal of Obstetrics and Gynecology
2024;59(9):692-701
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the effects and safety of dienogest on the volume and symptoms of ovarian endometrioma (OMA).Methods:The clinical data of 75 patients with OMA who underwent treatment with dienogest (2 mg/day) at the First Affiliated Hospital of Nanjing Medical University from July 1st 2020 to March 31st 2024 were retrospectively analysed, mainly comparing the changes in the volume of OMA and the visual analogue scale (VAS) scores of endometriosis-related pain before and after the treatment, as well as observing the changes in the blood biological indicators, liver and kidney function, coagulation function and changes in breast.Results:The median cyst volumes of the OMA patients at 3, 6 and 12 months of dienogest treatment were 13.21 cm 3 (volume reduction rate: 36.00%), 8.33 cm 3 (volume reduction rate: 56.00%) and 4.10 cm 3 (volume reduction rate: 77.62%), respectively, which were all significantly decreased from the pre-treatment period (all P<0.05). The VAS scores of pain of the OMA patients at 3, 6 and 12 months of dienogest treatment all were 0 mm. Blood cancer antigen 125 (CA 125) and cancer antigen 19-9 (CA 19-9) levels decreased progressively during treatment (all P<0.05). There were no statistical differences in the coagulation indexes, liver and kidney function indexes of the patients during dienogest treatment compared with those before treatment (all P>0.05). During the follow-up period, there were a few patients with changes in the growth sites or lesion category of the breast nodules, but there were no occurrence of breast cancer or precancerous lesions. Conclusion:Dienogest is effective in reducing OMA volume and alleviating endometriosis-related pain with few adverse effects.
